Cme (CME) Cash & Equivalents (2009 - 2026)

Cme (CME) has reported Cash & Equivalents for 18 consecutive years, with $2.1 billion the latest figure, recorded in Q2 2026.

• Quarterly Cash & Equivalents rose 8.22% year-over-year to $2.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.1 billion (up 8.22% YoY) and the FY2025 annual result came in at $4.4 billion, up 52.71% from the prior year.
• Cash & Equivalents declined to $2.1 billion in Q2 2026 per CME's latest filing, from $2.4 billion in the prior quarter.
• Over the last five years, Cash & Equivalents for CME reached as high as $4.4 billion in Q4 2025 and fell as low as $1.4 billion in Q1 2025.
• A 5-year average of $2.3 billion and a median of $2.1 billion in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents surged 118.46% — and 2023, when it slipped 23.49%.
• Year by year, Cash & Equivalents stood at $2.7 billion in 2022, then advanced by 7.05% to $2.9 billion in 2023, then decreased by 0.67% to $2.9 billion in 2024, then jumped by 52.71% to $4.4 billion in 2025, then plunged by 51.45% to $2.1 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $2.1 billion, $2.4 billion, and $4.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.